Back to Search Results
Study Complete
Sponsor ID
20020166

Treatment for Patients with Gynecological Malignancies Who Suffer from Anemia Due to Chemotherapy

Sponsor ID
20020166
Clinicaltrials.gov ID
NCT00121030
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.

Additional Study Details

Phase
Phase 2
Product
darbepoetin alfa
Type
Interventional
Masking
None (Open Label)
Enrollment
N/A
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Locations

No locations found.
Study Info
Age
18+ years
Condition
  • Anemia of Cancer
    • Show more
  • Genital Cancer
  • Anemia
    • Sex
    Assigned Female at Birth
    Trial Dates
    Oct 2002 - N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subjects receiving multi-cycle chemotherapy for gynecological cancer - Anemia due to chemotherapy (hgb less than or equal to 11.0 g/dL) - Expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment - Karnofsky Performance Scale (KPS) greater than or equal to 50% - Adequate renal function - Adequate liver function
    Exclusion Criteria:
    - Iron deficiency - Known positive test for human immunodeficiency virus (HIV) infection